AMAL Therapeutics is a Swiss biotech developing therapeutic vaccines, and aiming at overcoming the challenges around effective anti-cancer therapy by stimulating the immune system in a unique way, to create immunological memory. AMAL joined the Boehringer Ingelheim group of companies in 2019.

Products, services, technology

KISIMA®, a novel peptide/protein-based immunisation technology platform, enables the assembly within one chimeric fusion protein of 3 elements essential to generate potent immunity.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in